CHICAGO, Oct. 17, 2022 (GLOBE NEWSWIRE) — According to new market research report, “Market for diagnostics for sexually transmitted diseases by Disease Type (CT/NG, Gonorrhea, Syphilis, Genital Herpes, Hepatitis B, HIV/AIDS, HPV), End User (Laboratory, PoC), and Geography – Global Forecast to 2027” is expected to reach $99,431.6 million by 2027 $91,441.5 million in 2022 at a CAGR of 5.6% over the forecast period.
Download PDF brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=117297162
Scope of Sexually Transmitted Diseases Market Report:
| report metrics | details |
| market size | $99,431.6 million by 2027 |
| CAGR | 5.6% |
| Historical data | 2019-2020 |
| base year | 2021 |
| forecast period | 2022-2027 |
| Forecast Units | Value (Billion USD) |
| report coverage | Sales Forecast, Competitive Landscape, Growth Factors and Trends |
| Covered Segments | By device type, by test type, by disease type, by end user, by geography |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa |
| Key companies in profile/suppliers | Abbott Laboratories (US) | F. Hoffmann-La Roche AG (Switzerland) | bioMérieux SA (France) | Thermo Fisher Scientific Inc. (USA) | Danaher Corporation (US) | Quidel Corporation(USA) | Hologic | Inc. (US) | Bio-Rad Laboratories | Inc. (US) | QIAGEN (Netherlands) | DiaSorin SpA (Italy) | Grifols SA (Spain). |
The STD diagnostics market is being driven by factors such as the global prevalence of HIV, CT/NG and other STDs and growing awareness of early disease detection, shifting focus from centralized labs to decentralized POC testing and increasing technological advancements definitely. On the other hand, an adverse reimbursement scenario is expected to limit the market growth to some extent in the coming years. The increase in cases of STDs in the global population is expected to drive the growth of STD testing market. Increasing government initiatives to introduce new diagnostic kits and tests are…
